SuppreMol Receives Orphan Drug Designation for SM101
"The orphan drug designation is an important recognition of our approach, offering increased opportunity to engage the EMEA in discussions concerning its further clinical development," said Peter Buckel, CEO of SuppreMol.
The EMEA's orphan drug program is designed to promote the development of drugs to treat rare and life-threatening or very serious conditions (prevalence: < 5 in 10,000 people in the European Union). The designation provides EU market exclusivity for up to ten years in the given indication. Other potential benefits include a reduction in fees associated with various aspects of the regulatory process, including the application for marketing approval as well as EMEA guidance in preparing protocols concerning studies relevant for approval.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.